This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Jul 2012

Lupin Receives FDA Approval for Generic LYRICA

Lupin's Pregabalin Capsules are the AB-rated generic equivalent of LYRICA capsules which had annual U.S sales of approximately $1.8 billion for the twelve months ending March 2012.

Lupin Ltd. has announced that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the FDA to market a generic version of C.P. Pharmaceuticals C.V., LYRICA (Pregabalin) capsules.

 

Lupin's Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg are the AB-rated generic equivalent of LYRICA capsules, which is indicated for neuropathic pain associated with diabetic peripheral neuropathy, post herpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and fibromyalgia.

 

LYRICA Capsules had annual U.S sales of approximately $1.8 billion for the twelve months ending M

Related News